Document is current
Any future updates will be listed below
-
Authors
Losa, Marco https://orcid.org/0000-0003-3428-418X
Emmenegger, Marc https://orcid.org/0000-0002-6073-8811
De Rossi, Pierre
Schürch, Patrick M https://orcid.org/0000-0003-3895-2149
Serdiuk, Tetiana
Pengo, Niccolò
Capron, Danaëlle https://orcid.org/0009-0000-2674-2588
Bieli, Dimitri
Bargenda, Niklas https://orcid.org/0000-0001-9915-092X
Rupp, Niels J
Carta, Manfredi C
Frontzek, Karl J
Lysenko, Veronika
Reimann, Regina R
Schwarz, Petra https://orcid.org/0000-0003-1686-8624
Nuvolone, Mario https://orcid.org/0000-0001-8334-1684
Westermark, Gunilla T
Nilsson, K Peter R
Polymenidou, Magdalini https://orcid.org/0000-0003-1271-9445
Theocharides, Alexandre PA
Hornemann, Simone https://orcid.org/0000-0002-2674-9891
Picotti, Paola https://orcid.org/0000-0002-4109-3552
Aguzzi, Adriano https://orcid.org/0000-0002-0344-6708
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (179040)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (210931)
NOMIS Stiftung
Baugarten Stiftung (USZF27101)
Swiss Personalized Health Network (SPHN) driver grant (2017DRI1)
- License Information
-
More Information
Article History
Received: 28 May 2024
Revised: 5 July 2024
Accepted: 10 July 2024
First Online: 30 July 2024
Disclosure and competing interests statement
: Adriano Aguzzi is a founder, shareholder, director, and consultant for Mabylon AG, which has developed the anti-ASC monoclonal antibody used in this study. NP, DC and DB are employees of Mabylon AG. Adriano Aguzzi is a member of the Advisory Editorial Board of EMBO Molecular Medicine. This has no bearing on the editorial consideration of this article for publication.
